Bevacizumab (an anti-VEGF antibody) attenuated oedema caused by high permeability [246], while instillation of VEGF via anti-VEGFR2 antibodies protected mice against respiratory distress syndrome [247]. This evidence concerns the gene VEGFA and newborn respiratory distress syndrome.